¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"residual immunity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • individual immunity
    °³Àθ鿪, °³Ã¼¸é¿ª
  • infection immunity
    °¨¿°¸é¿ª
  • innate immunity
    ¼±Ãµ¸é¿ª
  • local immunity
    ±¹¼Ò¸é¿ª
  • maternal immunity
    ¸ð¼º¸é¿ª
  • nonspecific immunity
    ºñƯÀ̸鿪
  • native immunity
    °íÀ¯¸é¿ª
  • natural immunity
    ÀÚ¿¬¸é¿ª
  • opsonic immunity
    ¿É¼Ò´Ñ¸é¿ª
  • protective immunity
    ¹æ¾î¸é¿ª
  • passive immunity
    ¼öµ¿¸é¿ª
  • permanent immunity
    ¿µ±¸¸é¿ª
  • racial immunity
    ÀÎÁ¾¸é¿ª
  • relative immunity
    »ó´ë¸é¿ª
  • specific immunity
    ƯÀ̸鿪
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • impaired cellular immunity
    ¼¼Æ÷¸é¿ªºÎÀü
  • infection immunity
    °¨¿°¸é¿ª
  • innate immunity
    ¼±Ãµ¸é¿ª
  • local immunity
    ±¹¼Ò¸é¿ª
  • maternal immunity
    ¸ð¼º¸é¿ª
  • native immunity
    (¢¡innate immunity) ¼±Ãµ¸é¿ª
  • natural immunity
    ÀÚ¿¬¸é¿ª
  • nonspecific immunity
    ºñƯÀ̸鿪
  • opsonic immunity
    ¿É¼Ò´Ñ¸é¿ª
  • passive immunity
    ¼öµ¿¸é¿ª
  • permanent immunity
    ¿µ±¸¸é¿ª
  • protective immunity
    ¹æ¾î¸é¿ª
  • racial immunity
    ÀÎÁ¾¸é¿ª
  • relative immunity
    »ó´ë¸é¿ª
  • specific immunity
    ƯÀ̸鿪
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antitumor immunity
    Ç×Á¾¾ç(¼º) ¸é¿ª(¡­Øóæ¹).
  • antiviral immunity
    Ç×¹ÙÀÌ·¯½º¸é¿ª(¡­Øóæ¹).
  • antiviral immunity
    Ç×¹ÙÀÌ·¯½º¸é¿ª(~Øóæ¹)
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª.
  • gut immunity
    Àå°ü¸é¿ª
  • herd immunity
    ±ºÁý¸é¿ª, Áý´Ü¸é¿ª
  • herd immunity
    Áý´Ü¸é¿ª, ±ºÁý¸é¿ª, ¹«¸®¸é¿ª
  • immunity, cross
    ±³Â÷¸é¿ª
  • immunity, gut
    Àå°ü¸é¿ª
  • immunity, herd
    Áý´Ü¸é¿ª, ±ºÁý¸é¿ª, ¹«¸®¸é¿ª
  • immunity, humoral
    ü¾×¼º¸é¿ª
  • immunity, innate
    ¼±Ãµ¸é¿ª
  • immunity, local
    ±¹¼Ò¸é¿ª
  • immunity, maternal
    ¸ð¼º¸é¿ª
  • immunity, native
    ¼±Ãµ¸é¿ª
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • residual albuminuria
    ÀÜÁ¸´Ü¹é´¢(íÑðíÓ±ÛÜèñ).
  • residual antigen
    ÀÜ¿©Ç׿ø(íÑæ®ù÷ê«).
  • residual antigen
    ÀÜ·ùÇ׿ø, ÀÜÁ¸Ç׿ø
  • residual antigen
    ÀÜ¿©Ç׿ø(íÑæ®ù÷ê«).
  • residual astigmatism
    ÀÜ¿©³­½Ã
  • residual body
    ÀÜ·ùü(íÑ׺ô÷), ÀÜÁ¸Ã¼(íÑðíô÷)
  • residual body
    ÀÜ¿©¼Òü
  • residual carbon
    ÀÜ¿©Åº¼Ò(íÑæ®÷©áÈ).
  • residual chlorine
    ÀÜ·ù¿°¼Ò(ËöËôËçËÛ).
  • residual chromatin
    ¿°»öÁúÀÜ¿© (È£¿°±â¼º°ú¸³)
  • residual current
    ÀÜ·ùÀü·ù(íÑë§ï³êü).
  • residual cyst
    ÀÜ·ù³¶
  • residual cyst
    ÀÜ·ù³¶.
  • residual delirium
    ÀÜÀ缺 ¸Á»ó(íÑî¤àõØÍßÌ).
  • residual elengation
    ÀÜ·ù½ÅÀå(íÑë§ãßíå).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • passive immunity
    ¼öµ¿¸é¿ª(áôÔÑØóæ¹)
  • protective immunity
    º¸È£ ¸é¿ª¼º(ÜÁûÞØóæ¹àõ)
  • specific immunity
    ƯÀ̸鿪(÷åì¶Øóæ¹)
  • superinfection immunity
    Áß°¨¿° ¸é¿ª (ñìÊïæøØóæ¹)
  • transferred immunity
    ÀüÀÌ ¸é¿ª (ï®ì¹Øóæ¹)
  • transplantation immunity
    ÀÌ½Ä ¸é¿ª(ì¹ãÕØóæ¹)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
immun immune, immunity, immunization
FRC Functional Residual Capacity
LCP Disease Legg-Calve-Perthes Disease
  ? Stages of LCP Disease(= Juvenile Idiopathic AVN)
&nb...
RIND Residual(= Reversible) Ischemic Neurologic Deficit
RV   1) Residual Volume
  2) Right Ventricle
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RVF Residual Volume Fraction
ROFA Residual oil fly ash
RRF Residual renal function
PVR post void residual
PVR post-void residual urine volume
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • active immunity
    ´Éµ¿ ¸é¿ª
    Ç׿ø Àڱؿ¡ ¹ÝÀÀÇÏ¿© »ý»êµÈ Ç×ü³ª ¸é¿ª ¸²ÇÁ°è ¼¼Æ÷ÀÇ Á¸Àç·Î ÀÎÇÑ È¹µæ¸é¿ª. »ç¶÷¿¡ ´ëÇØ¼­ ¹é½ÅÀ̳ª µ¶¼ºÀ¸·Î ¸é¿ªÇÏ´Â °ÍÀ¸·Î ÀÚ½ÅÀÇ ¸öÀ¸·Î ¸é¿ªÀ» ¸¸µé¾î³»¹Ç·Î È¿°ú´Â ¿À·¡ Áö¼ÓµÈ´Ù.
  • adoptive immunity
    ÀÔ¾ç ¸é¿ª
    µ¿Á¾ À̽Ä. ¿¹¸¦ µé¸é ¸¶¿ì½ºÀÇ ÇǺΠÀ̽ÄÀ» Çϸé ÀÌ½Ä ÈÄ 10ÀÏ Á¤µµ¿¡¼­ ÀÌ½ÄÆíÀº Å»¶ôÇÏ°í ¼ÒÀ§ °ÅºÎ Çö»óÀÌ ³ªÅ¸³­´Ù. ÀÌ ¸¶¿ì½º¿¡¼­ ¸²ÇÁ±¸¸¦ ¶¼¼­ ±×°ÍÀ» ¹Ìó¸® µ¿°è ¸¶¿ì½º·Î ÀÌÀÔÇÏ°í ±× µ¿¹°¿¡ ÃÖÃÊÀÇ ÇǺΠÀ̽İú °°Àº ÇǺθ¦ À̽ÄÇØÁÖ¸é ÀÌ °æ¿ìµµ °­ÇÑ °ÅºÎ ¹ÝÀÀÀÌ Àüº¸´Ùµµ »¡¸® ÀϾ¸ç À̽ÄÈÄ 3-4ÀÏ·Î ÀÌ½ÄÆíÀÇ ÆÄ±«°¡ ³ªÅ¸³­´Ù. À̰ÍÀº °ÅºÎ Çö»óÀÌ ¸é¿ª ¹ÝÀÀ¿¡ ÀÇÇØ¼­ ÀϾ´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. ÀÌ¿Í °°ÀÌ °¨ÀÛ ¸²ÇÁ±¸¿¡ ÀÇÇØ¼­ ¸é¿ª´ÉÀ» ´Ù¸¥ °³Ã¼·Î Àü´ÞÇÏ´Â °ÍÀ» ¾çÀÚ ¸é¿ªÀ̶ó ÇÑ´Ù.
  • allogenic immunity
    µ¿Á¾ ¸é¿ª
  • antiviral immunity
    Ç×¹ÙÀÌ·¯½º ¸é¿ª
  • cell mediated immunity
    ¼¼Æ÷ ¸Å°³ ¸é¿ª, ¼¼Æ÷ ¸Å°³¼º ¸é¿ª ÀÛ¿ë, ¼¼Æ÷¼º ¸é¿ª
    Ç׿øÀÌ T Àӯı¸¸¦ ÀÚ±ØÇÏ¸é ¸é¿ª ±Û·ÎºÒ¸°À» ÇÕ¼º ºÐºñÇÏ´Â °ÍÀÌ ¾Æ´Ï°í Àӯı¸ ÀÚ½ÅÀÌ Ç×ü·Î ÀÛ¿ëÇÏ´Â °¨ÀÛ Àӯı¸°¡ µÇ´Â °ÍÀÌ Ã¼¾×¼º ¸é¿ª°úÀÇ Â÷ÀÌ·Î, ü¾×¼º ¸é¿ªÀÌ ÁÖ·Î ±Þ¼º ¼¼±Õ¼º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±âÀüÀε¥ ºñÇØ¼­ ¼¼Æ÷¼º ¸é¿ªÀº ¸¸¼º ¼¼±Õ¼º Áúȯ, Á¶Á÷ À̽Ä, ¾Ï ¼¼Æ÷, °õÆÎÀÌ Áúȯ, ƯÈ÷ ¹ÙÀÌ·¯½º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±âÀüÀÌ´Ù.
  • cell-mediated immunity
    ¼¼Æ÷ ¸Å°³ ¸é¿ª, ¼¼Æ÷ ¸Å°³¼º ¸é¿ª
  • congenital immunity
    ¼±Ãµ¼º ¸é¿ª
  • histogenous immunity
    Á¶Á÷ ¸é¿ª
  • homologous immunity
    µ¿Á¾ ¸é¿ª
  • immunity deficiency
    ¸é¿ª °áÇÌ
    µ¿ÀǾî=immunodeficiency.
  • inborn immunity
    ¼±Ãµ¼º ¸é¿ª
    °³Ã¼ÀÇ À¯ÀüÀû ¼ÒÁú¿¡ ±âÀÎÇÏ´Â ¸é¿ª.
  • infection immunity
    °¨¿° ¸é¿ª
    ÀÌ¹Ì Ç׿øÀÌ °°°Å³ª °ü·ÃµÈ Ç׿øÀ» °¡Áø ¹Ì»ý¹°¿¡ ÀÇÇÑ ÁúȯÀÌ Á¸ÀçÇϱ⠶§¹®¿¡ Àç°¨¿°¿¡ ´ëÇÏ¿© ÀúÇ×·ÂÀÌ ÀÖ´Â »óÅÂ.
  • local immunity
    ±¹¼Ò ¸é¿ª
  • mucosal immunity
    Á¡¸· ¸é¿ª
  • natural active immunity
    ÀÚ¿¬ ´Éµ¿ ¸é¿ª
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
residual schizophrenia Blunted or inappropriate affect, social withdrawal, eccentric behaviour, or loose associations, but without prominent psychotic symptoms, as the remains of former psychotic symptoms of schizophrenia.
(05 Mar 2000)
residual urine Urine remaining in the bladder at the end of micturition in cases of prostatic obstruction, bladder atony, etc.
(05 Mar 2000)
residual volume The volume of air remaining in the lungs at the end of a maximal expiration. Common abbreviation is rv.
(12 Dec 1998)
neoplasm, residual Remnant of a tumour or cancer after primary, potentially curative therapy. (dr. Daniel masys, written communication)
(12 Dec 1998)
functional residual air The volume of air remaining in the lungs at the end of a normal, quiet expiration. It is the sum of the residual volume and the expiratory reserve volume. Common abbreviation is frc.
(12 Dec 1998)
functional residual capacity The volume of air remaining in the lungs at the end of a normal, quiet expiration. It is the sum of the residual volume and the expiratory reserve volume. Common abbreviation is frc.
(12 Dec 1998)
acquired immunity <immunology> A form of cellular defense which identifies certain foreign substances (antigens) as harmful to the body. For this reason, the body can acquire resistance to a particular foreign agent.
These foreign agents are then attacked by sensitised T lymphocytes (cellular immunity). White blood cells, plasma cells, B lymphocytes and other specialised immune system cells act in concert with T lymphocytes to produce antibodies (humoral immunity) that attach to the antigen directing T-cells to attack.
Antibodies also stimulate the release of special chemical mediators in the blood (for example complement, interferon) that further enhance antigen destruction.
(13 Nov 1997)
active immunity <immunology> An organisms resistance to disease or infection, developed because the organisms immune system has produced antibodies after an infection or innoculation.
(06 May 1997)
adoptive immunity <immunology> Immunity to disease or infection conferred on a previously non-immune individual by transferring lymphocytes from a previously immune individual to the non-immune individual.
(15 Jan 1998)
allograft immunity <immunology> The recipient's immune system rejects tissue grafted from a genetically dissimilar donor (of the same species) and stages an immune attack against it.
(09 Oct 1997)
antiviral immunity Immunity resulting from virus infection, either naturally acquired or produced by intentional vaccination; compared to some bacterial immunity's, it is of relatively long duration, but this may be the result of infection-immunity rather than being peculiar to virus infection per se, since it occurs also in bacterial immunity after infections such as typhoid fever.
(05 Mar 2000)
artificial active immunity See: acquired immunity.
(05 Mar 2000)
artificial passive immunity See: acquired immunity.
(05 Mar 2000)
bacteriophage immunity The state induced in a bacterium by lysogenization, the lysogenic bacterium being insusceptible to further lysogenization or to a lytic cycle by a superinfecting bacteriophage, in contradistinction to bacteriophage resistance.
(05 Mar 2000)
general immunity Immunity associated with widely diffused mechanisms that tend to protect the body as a whole, as compared with local immunity.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • residual radiation
    ÀÜ·ù¹æ»ç¼±
  • residual ray
    ÀÜ·ù¼±
  • residual security
    ÀÜ¿© Áõ±Ç(º¸Åë ÁÖ³ª Àüȯ »çä)
  • residual sovereignty
    ÀáÀç ÁÖ±Ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á